Novo Nordisk suffers Phase 3 setback as CV inflammation drug fails
Novo Nordisk’s anti-inflammatory drug for cardiovascular inflammation unexpectedly failed in a Phase 3 trial designed to prove a link between inflammation and heart disease, marking a setback for its cardiovascular program and potentially reshaping investor expectations.